Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Cumming

Showing results (131-140 of 192) with videos related to

Pageof 20
Sort By:
Nuclear Medicine Communications|September 1, 1985
Development of a 99Tcm-labelled radiopharmaceutical for cerebral blood flow imagingD P Nowotnik, L R Canning, S A Cumming, et al.
Journal of Huntington'S Disease|February 13, 2021
Approaches to Sequence the HTT CAG Repeat Expansion and Quantify Repeat Length VariationMarc Ciosi, Sarah A Cumming, Afroditi Chatzi, et al.
Nuclear Medicine Communications|August 1, 1985
Cerebral uptake and retention of 99Tcm-hexamethylpropyleneamine oxime (99Tcm-HM-PAO)R A Holmes, S B Chaplin, K G Royston, et al.
Neurology|August 10, 2019
Genetic determinants of disease severity in the myotonic dystrophy type 1 OPTIMISTIC cohortSarah A Cumming, Cecilia Jimenez-Moreno, Kees Okkersen, et al.
Plos One|April 15, 2020
Towards development of a statistical framework to evaluate myotonic dystrophy type 1 mRNA biomarkers in the context of a clinical trialAdam Kurkiewicz, Anneli Cooper, Emily McIlwaine, et al.
Bioorganic & Medicinal Chemistry|September 19, 2025
Generation of a potent & selective series of IRAK4 inhibitors based on a structure based, hybridization approachIna Terstiege, Anna Aagaard, Kristina Berggren, et al.
Neurology. Genetics|April 22, 2021
Associations Between Variant Repeat Interruptions and Clinical Outcomes in Myotonic Dystrophy Type 1Stephan Wenninger, Sarah A Cumming, Kristina Gutschmidt, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 28, 2017
CRISPR/Cas9-Induced (CTG⋅CAG)<sub>n</sub> Repeat Instability in the Myotonic Dystrophy Type 1 Locus: Implications for Therapeutic Genome EditingEllen L van Agtmaal, Laurène M André, Marieke Willemse, et al.
Neuromuscular Disorders : NMD|April 1, 2022
Clinical and neuroradiological correlates of sleep in myotonic dystrophy type 1Mark J Hamilton, Antonio Atalaia, John McLean, et al.
Bioorganic & Medicinal Chemistry Letters|September 7, 2010
A novel series of positive modulators of the AMPA receptor: structure-based lead optimizationCraig Jamieson, Robert A Campbell, Iain A Cumming, et al.
Pageof 20

Showing results (131-140 of 192) with videos related to

Sort By:
Pageof 20
Nuclear Medicine Communications|September 1, 1985
Development of a 99Tcm-labelled radiopharmaceutical for cerebral blood flow imagingD P Nowotnik, L R Canning, S A Cumming, et al.
Journal of Huntington'S Disease|February 13, 2021
Approaches to Sequence the HTT CAG Repeat Expansion and Quantify Repeat Length VariationMarc Ciosi, Sarah A Cumming, Afroditi Chatzi, et al.
Nuclear Medicine Communications|August 1, 1985
Cerebral uptake and retention of 99Tcm-hexamethylpropyleneamine oxime (99Tcm-HM-PAO)R A Holmes, S B Chaplin, K G Royston, et al.
Neurology|August 10, 2019
Genetic determinants of disease severity in the myotonic dystrophy type 1 OPTIMISTIC cohortSarah A Cumming, Cecilia Jimenez-Moreno, Kees Okkersen, et al.
Plos One|April 15, 2020
Towards development of a statistical framework to evaluate myotonic dystrophy type 1 mRNA biomarkers in the context of a clinical trialAdam Kurkiewicz, Anneli Cooper, Emily McIlwaine, et al.
Bioorganic & Medicinal Chemistry|September 19, 2025
Generation of a potent & selective series of IRAK4 inhibitors based on a structure based, hybridization approachIna Terstiege, Anna Aagaard, Kristina Berggren, et al.
Neurology. Genetics|April 22, 2021
Associations Between Variant Repeat Interruptions and Clinical Outcomes in Myotonic Dystrophy Type 1Stephan Wenninger, Sarah A Cumming, Kristina Gutschmidt, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 28, 2017
CRISPR/Cas9-Induced (CTG⋅CAG)<sub>n</sub> Repeat Instability in the Myotonic Dystrophy Type 1 Locus: Implications for Therapeutic Genome EditingEllen L van Agtmaal, Laurène M André, Marieke Willemse, et al.
Neuromuscular Disorders : NMD|April 1, 2022
Clinical and neuroradiological correlates of sleep in myotonic dystrophy type 1Mark J Hamilton, Antonio Atalaia, John McLean, et al.
Bioorganic & Medicinal Chemistry Letters|September 7, 2010
A novel series of positive modulators of the AMPA receptor: structure-based lead optimizationCraig Jamieson, Robert A Campbell, Iain A Cumming, et al.
Pageof 20